Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plus Therapeutics ( (PSTV) ) has issued an update.
On April 9, 2026, Plus Therapeutics announced the appointment of Eric J. Daniels, M.D., as chief development officer, effective April 20, 2026, tasking him with overseeing development and ultimate approval of the company’s pharmaceutical pipeline. Daniels brings extensive experience from senior roles at Kiora Pharmaceuticals, Bayon Therapeutics, OccuRx, Okogen, Bimini, and Tensys Medical, supported by medical and business degrees from the University of California system.
In connection with his appointment, Plus Therapeutics entered into an employment agreement on April 8, 2026, providing Daniels with a $460,000 base salary, a 40% target annual bonus, stock options for 20,000 shares, and 20,000 restricted stock units with multi-year vesting and a one-year cliff. The agreement also sets out a severance package and partial accelerated vesting of equity awards in the event of an involuntary termination, signaling a strategic, long-term investment in leadership to drive the company’s development strategy while aligning executive incentives with shareholder interests.
The most recent analyst rating on (PSTV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The score is weighed down primarily by very weak financial performance (zero 2025 revenue, widening losses, and accelerating cash burn) and a pronounced bearish technical trend (price far below key moving averages with negative MACD). Positive corporate developments, including FDA orphan designation for REYOBIQ and board strengthening, provide some support but are not enough to offset the current financial and price-trend risks.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc. is a pharmaceutical company focused on developing and securing regulatory approval for a pipeline of drug candidates. The company operates in the biotechnology and therapeutics industry, concentrating on advancing its pharmaceutical assets through clinical development to commercialization across targeted disease areas.
Average Trading Volume: 476,438
Technical Sentiment Signal: Sell
Current Market Cap: $21.75M
See more insights into PSTV stock on TipRanks’ Stock Analysis page.